Faculty

Institution

Unit

Venue

Michael Jung

Professor

University of California, Los Angeles

Affiliations

the College

California Nanosystems Institute (cnsi)

Molecular Biology Institute (mbi)

David Geffen School of Medicine

Molecular & Medical Pharmacology

Michael Jung is currently serving as a California Nanosystems Institute (Cnsi) Professor at University of California, Los Angeles.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael Jung

University of California, Los Angeles

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 599: Combination of Cdk4/6 Inhibitors With Biguanides for Treatment of Triple Negative Breast Cancer. Cancer Research (2024)

Mario Morales MartinezEduardo Mauricio GonzalezGang DengGaoyuan MaHyunsoo KimLinsey StilesNalo HamiltonMichael E. JungRichard J. PietrasDiana C. Marquez-Garban

cancer treatmentdrug targetingradiation oncologyclinical researchbreast cancermedicinal researchcancer managementoncologyanti-cancer agentscancer researchcancer immunotherapycancer carepharmacologyenzyme inhibitioncancer biology

Dddr-43. Eras-801 is a Selective Brain-Penetrant Egfr Inhibitor With Improved Activity Against Egfr Extracellular Domain-Mutant Glioblastoma. Neuro-Oncology (2024)

Quincy OkobiDimitri CadetLorenz UrnerMichael JungTimothy CloughesyDavid Nathanson

medicinal researchtumor suppressorsimproved activitytumor biologybrain tumor researchoncogenesmolecular biologycancer discoverytherapeutic targetsneuro-oncologybrain pathologyneurologygliomascancer treatmenttumor targetingclinical neurologyneuroscienceoncologymolecular neurodegeneration

Abstract 510: Targeting Metabolic Vulnerabilities to Reduce Triple Negative Breast Cancer Health Disparities. Cancer Research (2023)

Diana C. Márquez-GarbanGang DengLorena P. BurtonGaoyuan MaVishaka MuhunthanBegonya Comin-AnduixGabriela LlarenaNeda MoatamedJennifer MurphyNalo HamiltonDaivd ShackelfordMichael E. JungRichard J. Pietras

health sciencesmetabolic vulnerabilitiesmetabolismbreast cancercancer preventiononcologytumor targetingcancer researchpharmacology

Ccdc 2157502: Experimental Crystal Structure Determination. The Cambridge Structural Database (2023)

Rao, YuPalumbo, Chad T.Venkatesh, AmritKeener, MeganStevanato, GabrieleChauvin, Anne-SophieMenzildjian, GeorgesKuzin, SergeiYulikov, MaximJeschke, GunnarLesage, AnneMazzanti, MarinellaEmsley, Lyndon

biophysicscrystallographycrystal researchccdc 2157502deposited datasetcrystal structureschemistrycrystal engineeringstructure determinationstructural chemistrychemical structurecrystal diffraction studystructure elucidation

Data From Cytotoxic Properties of a Deptor-Mtor Inhibitor in Multiple Myeloma Cells. (2023)

Yijiang ShiTracy R. Daniels-WellsPatrick FrostJihye LeeRichard S. FinnCarolyne BardelebenManuel L. PenichetMichael E. JungJoseph GeraAlan Lichtenstein

cytotoxic propertiesoncologypharmacologymultiple myeloma cellsdeptor-mtor inhibitor

Development of a Novel Histone Deacetylase Inhibitor Unveils the Role of Hdac11 in Alleviating Depression by Inhibition of Microglial Activation. Biomedicine & Pharmacotherapy (2023)

Soo Yeon BaekJeehee LeeTaegwan KimHyelim LeeHoon-Seong ChoiHahnbeom ParkMinseob KohEunha KimMichael E. JungDimitrios IliopoulosJeong-Yeon LeeJonghoon KimSanghee Lee

clinical researchpsychopathologymedicinal researchpharmacological researchmicroglial activationclinical pharmacologypharmacologymedicineclinical therapeuticspharmaceutical sciencespsychopharmacologydepressionneuropsychopharmacologybiological psychiatrydrug discoveryneuropharmacologypharmacotherapypsychotropic medicationimmunology

Figure Legends From an Essential Requirement for the Scap/Srebp Signaling Axis to Protect Cancer Cells From Lipotoxicity. (2023)

Kevin J. WilliamsJoseph P. ArgusYue ZhuMoses Q. WilksBeth N. MarboisAutumn G. YorkYoko KidaniAlexandra L. PourziaDavid AkhavanDominique N. LisieroEvangelia KomisopoulouAmy H. HenkinHoracio SotoBrian T. ChamberlainLaurent VergnesMichael E. JungJorge Z. TorresLinda M. LiauHeather R. ChristofkRobert M. PrinsPaul S. MischelKaren ReueThomas G. GraeberSteven J. Bensinger

signal transductioncell signalingdermatologycancer researchtumor biologysignaling pathwayspharmacologyimmunologycancer biology

Figure S3 From a Novel Therapeutic Induces Deptor Degradation in Multiple Myeloma Cells With Resulting Tumor Cytotoxicity. (2023)

Mario I. VegaYijiang ShiPatrick FrostSara Huerta-YepezGabriela Antonio-AndresRogelio Hernandez-PandoJihye LeeMichael E. JungJoseph F. GeraAlan Lichtenstein

neurologyimmunotherapycancer treatmentdrug targetingmedicinal researchcancer managementoncologycancer immunotherapycancer researchcellular therapynovel therapiestherapeutic efficacytumor cytotoxicitypharmacologyimmunologymultiple myeloma cellstherapeutic targets

Supplemental Figure 5 From Cytotoxic Properties of a Deptor-Mtor Inhibitor in Multiple Myeloma Cells. (2023)

Yijiang ShiTracy R. Daniels-WellsPatrick FrostJihye LeeRichard S. FinnCarolyne BardelebenManuel L. PenichetMichael E. JungJoseph GeraAlan Lichtenstein

cytotoxic propertiesoncologypharmacologymultiple myeloma cellsdeptor-mtor inhibitordrug discovery

Supplementary Methods From Arn-509: A Novel Antiandrogen for Prostate Cancer Treatment. (2023)

Nicola J. CleggJohn WongvipatJames D. JosephChris TranSamedy OukAnna DilhasYu ChenKate GrillotEric D. BischoffLing CaiAnna AparicioSteven DorowVivek AroraGang ShaoJing QianHong ZhaoGuangbin YangChunyan CaoJohn SensintaffarTeresa WasielewskaMark R. HerbertCeline BonnefousBeatrice DarimontHoward I. ScherPeter Smith-JonesMark KlangNicholas D. SmithElisa De StanchinaNian WuOuathek OuerfelliPeter J. RixRichard A. HeymanMichael E. JungCharles L. SawyersJeffrey H. Hager

prostate cancer treatmentcancer treatmentsupplementary methodsurologydrug targetingprostate canceroncologypharmacotherapypharmacology

1
2
3
4
5
43
10 / page

Michael Jung

Professor

University of California, Los Angeles

Affiliations

the College

California Nanosystems Institute (cnsi)

Molecular Biology Institute (mbi)

David Geffen School of Medicine

Molecular & Medical Pharmacology

Michael Jung is currently serving as a California Nanosystems Institute (Cnsi) Professor at University of California, Los Angeles.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael Jung

University of California, Los Angeles

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 599: Combination of Cdk4/6 Inhibitors With Biguanides for Treatment of Triple Negative Breast Cancer. Cancer Research (2024)

Mario Morales MartinezEduardo Mauricio GonzalezGang DengGaoyuan MaHyunsoo KimLinsey StilesNalo HamiltonMichael E. JungRichard J. PietrasDiana C. Marquez-Garban

Dddr-43. Eras-801 is a Selective Brain-Penetrant Egfr Inhibitor With Improved Activity Against Egfr Extracellular Domain-Mutant Glioblastoma. Neuro-Oncology (2024)

Quincy OkobiDimitri CadetLorenz UrnerMichael JungTimothy CloughesyDavid Nathanson

Abstract 510: Targeting Metabolic Vulnerabilities to Reduce Triple Negative Breast Cancer Health Disparities. Cancer Research (2023)

health sciencesmetabolic vulnerabilitiesmetabolismbreast cancercancer preventiononcologytumor targetingcancer researchpharmacology

Ccdc 2157502: Experimental Crystal Structure Determination. The Cambridge Structural Database (2023)

Rao, YuPalumbo, Chad T.Venkatesh, AmritKeener, MeganStevanato, GabrieleChauvin, Anne-SophieMenzildjian, GeorgesKuzin, SergeiYulikov, MaximJeschke, GunnarLesage, AnneMazzanti, MarinellaEmsley, Lyndon

Data From Cytotoxic Properties of a Deptor-Mtor Inhibitor in Multiple Myeloma Cells. (2023)

Yijiang ShiTracy R. Daniels-WellsPatrick FrostJihye LeeRichard S. FinnCarolyne BardelebenManuel L. PenichetMichael E. JungJoseph GeraAlan Lichtenstein

cytotoxic propertiesoncologypharmacologymultiple myeloma cellsdeptor-mtor inhibitor

Development of a Novel Histone Deacetylase Inhibitor Unveils the Role of Hdac11 in Alleviating Depression by Inhibition of Microglial Activation. Biomedicine & Pharmacotherapy (2023)

Soo Yeon BaekJeehee LeeTaegwan KimHyelim LeeHoon-Seong ChoiHahnbeom ParkMinseob KohEunha KimMichael E. JungDimitrios IliopoulosJeong-Yeon LeeJonghoon KimSanghee Lee

Figure Legends From an Essential Requirement for the Scap/Srebp Signaling Axis to Protect Cancer Cells From Lipotoxicity. (2023)

signal transductioncell signalingdermatologycancer researchtumor biologysignaling pathwayspharmacologyimmunologycancer biology

Figure S3 From a Novel Therapeutic Induces Deptor Degradation in Multiple Myeloma Cells With Resulting Tumor Cytotoxicity. (2023)

Mario I. VegaYijiang ShiPatrick FrostSara Huerta-YepezGabriela Antonio-AndresRogelio Hernandez-PandoJihye LeeMichael E. JungJoseph F. GeraAlan Lichtenstein

Supplemental Figure 5 From Cytotoxic Properties of a Deptor-Mtor Inhibitor in Multiple Myeloma Cells. (2023)

Yijiang ShiTracy R. Daniels-WellsPatrick FrostJihye LeeRichard S. FinnCarolyne BardelebenManuel L. PenichetMichael E. JungJoseph GeraAlan Lichtenstein

cytotoxic propertiesoncologypharmacologymultiple myeloma cellsdeptor-mtor inhibitordrug discovery

Supplementary Methods From Arn-509: A Novel Antiandrogen for Prostate Cancer Treatment. (2023)

prostate cancer treatmentcancer treatmentsupplementary methodsurologydrug targetingprostate canceroncologypharmacotherapypharmacology

1
2
3
4
5
43
10 / page

Similar Faculty Members

Richard B. Silverman

Institution

Northwestern University

pharmacology

medicinal chemistry

Jianfeng Cai

Institution

University of South Florida

protein-protein interactions

biomolecular engineering

Shantu Amin

Institution

Pennsylvania State University

cancer letter

polycyclic aromatic hydrocarbon

Charles E. McKenna

Institution

University of Southern California

future medicinal chemistry

medicinal chemistry

Nicholas Farrell

Institution

Virginia Commonwealth University

clinical infectious disease

infectious diseases (medical specialty)

David J. Waxman

Institution

Boston University

molecular cancer

cancer genomics

Anthony E. Pegg

Institution

Pennsylvania State University

cancer letter

toxicological mechanism

Iwao Ojima

Institution

Stony Brook University

organic chemistry

medicinal chemistry

Lawrence J. Marnett

Institution

Vanderbilt University

anti-inflammatory agent

biochemistry

Shahriar Mobashery

Institution

University of Notre Dame

pharmacology

biochemistry

Similar Faculty Members

Richard B. Silverman

Institution

Northwestern University

pharmacology

medicinal chemistry

Jianfeng Cai

Institution

University of South Florida

protein-protein interactions

biomolecular engineering

Shantu Amin

Institution

Pennsylvania State University

cancer letter

polycyclic aromatic hydrocarbon

Charles E. McKenna

Institution

University of Southern California

future medicinal chemistry

medicinal chemistry

Nicholas Farrell

Institution

Virginia Commonwealth University

clinical infectious disease

infectious diseases (medical specialty)

David J. Waxman

Institution

Boston University

molecular cancer

cancer genomics

Anthony E. Pegg

Institution

Pennsylvania State University

cancer letter

toxicological mechanism

Iwao Ojima

Institution

Stony Brook University

organic chemistry

medicinal chemistry

Lawrence J. Marnett

Institution

Vanderbilt University

anti-inflammatory agent

biochemistry

Shahriar Mobashery

Institution

University of Notre Dame

pharmacology

biochemistry